

Available online at www.sciencedirect.com



Metabolism Clinical and Experimental

Metabolism Clinical and Experimental 54 (2005) 1694

www.elsevier.com/locate/metabol

## Erratum

In the December 2004 issue of *Metabolism*, in the article "Antidiabetic and Adipogenic Properties in a Newly Synthesized Thiazolidine Derivative, FPFS-410" by

Norisada et al (*Metabolism* 2004;53:1532-7), Fig. 2 on page 1535 should have appeared in color. The figure is reproduced here.




Fig. 2. A, The effect of FPFS-410 on adipogenesis. FPFS 410 (30  $\mu$ mol/L) was added to postconfluent 3T3-L1 cells for 2 days at indicated periods with stimulation by inducers indicated. All cells were fixed and stained with oil red O at day 8. B, Oil red O binding to lipid was extracted with 2-propanol followed by quantification by measuring absorbance at 510 nm. Data are presented as mean  $\pm$  SEM. C, The effects of FPFS-410 on the expression of transcription factor regulating adipogenesis in 3T3-L1 preadipocytes. 3T3-L1 cells were treated with vehicle of 30  $\mu$ mol/L FPFS-410 from day 0 to day 2 (left panels) or with vehicle or 100  $\mu$ mol/L pioglitazone from day -2 to day 0 (right panels) in IB + DX, DX + INS, or IB + DX + INS conditions. Cells were harvested at day 2 and subjected to SDS-PAGE followed by immunoblot to analyze the expression levels of transcription factors. V indicates vehicle; FP, FPFS-410; Pio, pioglitazone.